Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Klaus Zorn-Pauly is active.

Publication


Featured researches published by Klaus Zorn-Pauly.


Proteomics | 2010

Lysophosphatidic acid receptor activation affects the C13NJ microglia cell line proteome leading to alterations in glycolysis, motility, and cytoskeletal architecture

Eva Bernhart; Manfred Kollroser; Gerald N. Rechberger; Helga Reicher; Akos Heinemann; Petra Schratl; Seth Hallström; Andrea Wintersperger; Christoph Nusshold; Trevor DeVaney; Klaus Zorn-Pauly; Roland Malli; Wolfgang F. Graier; Ernst Malle; Wolfgang Sattler

Microglia, the immunocompetent cells of the CNS, are rapidly activated in response to injury and microglia migration towards and homing at damaged tissue plays a key role in CNS regeneration. Lysophosphatidic acid (LPA) is involved in signaling events evoking microglia responses through cognate G protein‐coupled receptors. Here we show that human immortalized C13NJ microglia express LPA receptor subtypes LPA1, LPA2, and LPA3 on mRNA and protein level. LPA activation of C13NJ cells induced Rho and extracellular signal‐regulated kinase activation and enhanced cellular ATP production. In addition, LPA induced process retraction, cell spreading, led to pronounced changes of the actin cytoskeleton and reduced cell motility, which could be reversed by inhibition of Rho activity. To get an indication about LPA‐induced global alterations in protein expression patterns a 2‐D DIGE/LC‐ESI‐MS proteomic approach was applied. On the proteome level the most prominent changes in response to LPA were observed for glycolytic enzymes and proteins regulating cell motility and/or cytoskeletal dynamics. The present findings suggest that naturally occurring LPA is a potent regulator of microglia biology. This might be of particular relevance in the pathophysiological context of neurodegenerative disorders where LPA concentrations can be significantly elevated in the CNS.


Journal of Molecular and Cellular Cardiology | 2014

If blocking potency of ivabradine is preserved under elevated endotoxin levels in human atrial myocytes

Susanne Scheruebel; Chintan N. Koyani; Seth Hallström; Petra Lang; Dieter Platzer; Heinrich Mächler; Karl Lohner; Ernst Malle; Klaus Zorn-Pauly; Brigitte Pelzmann

Lower heart rate is associated with better survival in patients with multiple organ dysfunction syndrome (MODS), a disease mostly caused by sepsis. The benefits of heart rate reduction by ivabradine during MODS are currently being investigated in the MODIfY clinical trial. Ivabradine is a selective inhibitor of the pacemaker current If and since If is impaired by lipopolysaccharide (LPS, endotoxin), a trigger of sepsis, we aimed to explore If blocking potency of ivabradine under elevated endotoxin levels in human atrial cardiomyocytes. Treatment of myocytes with S-LPS (containing the lipid A moiety, a core oligosaccharide and an O-polysaccharide chain) but not R595 (an O-chain lacking LPS-form) caused If inhibition under acute and chronic septic conditions. The specific interaction of S-LPS but not R595 to pacemaker channels HCN2 and HCN4 proves the necessity of O-chain for S-LPS–HCN interaction. The efficacy of ivabradine to block If was reduced under septic conditions, an observation that correlated with lower intracellular ivabradine concentrations in S-LPS- but not R595-treated cardiomyocytes. Computational analysis using a sinoatrial pacemaker cell model revealed that despite a reduction of If under septic conditions, ivabradine further decelerated pacemaking activity. This novel finding, i.e. If inhibition by ivabradine under elevated endotoxin levels in vitro, may provide a molecular understanding for the efficacy of this drug on heart rate reduction under septic conditions in vivo, e.g. the MODIfY clinical trial.


Biochemical Pharmacology | 2017

Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure

Chintan N. Koyani; Ewald Kolesnik; Gerald Wölkart; Niroj Shrestha; Susanne Scheruebel; Christopher Trummer; Klaus Zorn-Pauly; Astrid Hammer; Petra Lang; Helga Reicher; Heinrich Maechler; Klaus Groschner; Bernd Mayer; Peter P. Rainer; Harald Sourij; Wolfgang Sattler; Ernst Malle; Brigitte Pelzmann; Dirk von Lewinski

ABSTRACT Saxagliptin treatment has been associated with increased rate of hospitalization for heart failure in type 2 diabetic patients, though the underlying mechanism(s) remain elusive. To address this, we assessed the effects of saxagliptin on human atrial trabeculae, guinea pig hearts and cardiomyocytes. We found that the primary target of saxagliptin, dipeptidyl peptidase‐4, is absent in cardiomyocytes, yet saxagliptin internalized into cardiomyocytes and impaired cardiac contractility via inhibition of the Ca2+/calmodulin‐dependent protein kinase II‐phospholamban‐sarcoplasmic reticulum Ca2+‐ATPase 2a axis and Na+‐Ca2+ exchanger function in Ca2+ extrusion. This resulted in reduced sarcoplasmic reticulum Ca2+ content, diastolic Ca2+ overload, systolic dysfunction and impaired contractile force. Furthermore, saxagliptin reduced protein kinase C‐mediated delayed rectifier K+ current that prolonged action potential duration and consequently QTc interval. Importantly, saxagliptin aggravated pre‐existing cardiac dysfunction induced by ischemia/reperfusion injury. In conclusion, our novel results provide mechanisms for the off‐target deleterious effects of saxagliptin on cardiac function and support the outcome of SAVOR‐TIMI 53 trial that linked saxagliptin with the risk of heart failure.


British Journal of Pharmacology | 2017

Cardioprotective effects of 5‐hydroxymethylfurfural mediated by inhibition of L‐type Ca2+ currents

Gerald Wölkart; Astrid Schrammel; Chintan N. Koyani; S Scherübel; Klaus Zorn-Pauly; Ernst Malle; Brigitte Pelzmann; M Andrä; A Ortner; Bernd Mayer

The antioxidant 5‐hydroxymethylfurfural (5‐HMF) exerts documented beneficial effects in several experimental pathologies and is currently tested as an antisickling drug in clinical trials. In the present study, we examined the cardiovascular effects of 5‐HMF and elucidated the mode of action of the drug.


Biochemical and Biophysical Research Communications | 2016

Functional impairment of endothelial cells by the antimycotic amphotericin B.

Brigitte Pelzmann; Cristiana Maria Loredana Di Giuro; Klaus Zorn-Pauly; Christine Rossmann; Seth Hallström; Klaus Groschner; Nicola Fameli

We set out to determine the membrane potential (Vm) of the endothelial cell line EA.hy926 and its sensitivity to the antimycotic amphotericin B (AmB), a commonly used antifungal component in cell culture media. We measured the endothelial Vm under various experimental conditions by patch clamp technique and found that Vm of AmB-treated cells is (-12.1 ± 9.3) mV, while in AmB-untreated (control) cells it is (-57.1 ± 4.1) mV. In AmB-free extracellular solutions, Vm recovered toward control levels and this gain in Vm rapidly dissipated upon re-addition of AmB, demonstrating a rapid and reversible effect of AmB on endothelial Vm. The consequences of AmB dependent alterations in endothelial transmembrane potential were tested at the levels of Ca(2+) signaling, of nucleotide concentrations, and energy metabolism. In AmB-treated cells we found substantially reduced Ca(2+) entry (to about 60% of that in control cells) in response to histamine induced endoplasmic reticulum (ER) Ca(2+) depletion, and diminished the ATP-to-ADP ratio (by >30%). Our data demonstrate a marked and experimentally relevant dependence of basic functional parameters of cultured endothelial cells on the presence of the ionophoric antimycotic AmB. The profound and reversible effects of the widely used culture media component AmB need careful consideration when interpreting experimental data obtained under respective culture conditions.


Frontiers in Physiology | 2018

Sinoatrial Beat to Beat Variability Assessed by Contraction Strength in Addition to the Interbeat Interval

Helmut Ahammer; Susanne Scheruebel; Robert Arnold; Michael Mayrhofer-Reinhartshuber; Petra Lang; Ádám Dolgos; Brigitte Pelzmann; Klaus Zorn-Pauly

Beat to beat variability of cardiac tissue or isolated cells is frequently investigated by determining time intervals from electrode measurements in order to compute scale dependent or scale independent parameters. In this study, we utilize high-speed video camera recordings to investigate the variability of intervals as well as mechanical contraction strengths and relative contraction strengths with nonlinear analyses. Additionally, the video setup allowed us simultaneous electrode registrations of extracellular potentials. Sinoatrial node tissue under control and acetylcholine treated conditions was used to perform variability analyses by computing sample entropies and Higuchi dimensions. Beat to beat interval variabilities measured by the two recording techniques correlated very well, and therefore, validated the video analyses for this purpose. Acetylcholine treatment induced a reduction of beating rate and contraction strength, but the impact on interval variability was negligible. Nevertheless, the variability analyses of contraction strengths revealed significant differences in sample entropies and Higuchi dimensions between control and acetylcholine treated tissue. Therefore, the proposed high-speed video camera technique might represent a non-invasive tool that allows long-lasting recordings for detecting variations in beating behavior over a large range of scales.


American Journal of Physiology-heart and Circulatory Physiology | 2016

Letter to the editor: Accurate cell capacitance determination from a single voltage step: a reminder to avoid unnecessary pitfalls

Dieter Platzer; Klaus Zorn-Pauly

to the editor: Cell membrane capacitance C m is a fundamental property of excitable cells. It scales with the cell surface area and is therefore used for cell size estimation and most important for normalizing currents and conductances. Consequently, proper knowledge of C m is also crucial for


Archive | 2017

Beat-to-Beat Variability of Cardiomyocytes

Helmut Ahammer; Brigitte Pelzmann; Klaus Zorn-Pauly; Robert Arnold; Michael Mayrhofer-Reinhartshuber


Europace | 2017

P1707Interatrial differences in AF remodelling

Susanne Scheruebel; Chintan N. Koyani; Petra Lang; Eva Bernhart; S. Hallstroem; Heinrich Maechler; Gernot Plank; Klaus Zorn-Pauly; Brigitte Pelzmann


Archive | 2015

Septic Cardiomyopathy: from bench-to-bedside

Vasilios Papaioannou; Daniel De Backer; John Boyd; Anaïs Caillard; Erica C. Campos; Maria N. Celes; Gilles Clermont; James J. Douglas; Maria José Figueiredo; Ana Caroline Silva de Freitas; Etienne Gayat; Jamison J. Grailer; Jochen Hinkelbein; Matthieu Legrand; Alexandre Mebazaa; Andrea Morelli; Hélène Nougué; Sebastian Nuding; Maurizio Passariello; Klaus Zorn-Pauly; Brigitte Pelzmann; Simone G. Ramos; Susanne Scheruebel; Danilo Figueiredo Soave; Dahdouh Souheila; Sabri Soussi; Keith R. Walley; Peter A. Ward; Karl Werdan; Ursula Müller-Werdan

Collaboration


Dive into the Klaus Zorn-Pauly's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Chintan N. Koyani

Medical University of Graz

View shared research outputs
Top Co-Authors

Avatar

Ernst Malle

Medical University of Graz

View shared research outputs
Top Co-Authors

Avatar

Petra Lang

Medical University of Graz

View shared research outputs
Top Co-Authors

Avatar

Seth Hallström

Medical University of Graz

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dieter Platzer

Medical University of Graz

View shared research outputs
Top Co-Authors

Avatar

Eva Bernhart

Medical University of Graz

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge